الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 142 |  |  |
| | | from | 142 | | |
Abstract
Intravitreal injections of ranibizumab appeared to be a safe and effective option in the treatment of macular oedema secondary to retinal vein occlusion. Patients gained both functional and anatomical improvement during period of follow up after receiving the loading dose. Three patients showed no functional improvement with slight anatomical improvement. Three patients showed anatomical and functional recurrence. Age, gender, lens state, side of affected eye, systemic risk factors had statistically non-significant correlations with BCVA, CMT and IOP. The current study concluded that ranibizumab 0.5 mg is effective for treating macular edema secondary to retinal vein occlusion.